Abstract
Summary
seven patients with abnormally elevated blood lead and or urinary lead excretion values are presented who received CaEDTA orally, intravenously, or by both routes. This organic chelating agent effected a marked increase in urinary lead excretion by both routes. Intravenous administration was more effective than oral therapy. Preliminary results indicate that CaEDTA is the most effective agent proposed for the treatment of plumbism. Side-reactions were minimal with the dosage schedule employed.
Get full access to this article
View all access options for this article.